Director and Chief Scientific Officer
Haemalogix Ltd, Australia
Dr Rosanne Dunn is the Chief Scientific Officer at HaemaLogiX Ltd. She holds a BSc (Hons), MSc (Medical Science), PhD.
Rosanne has more than 20 years of experience in the fields of immunology, haematology, translational medicine and drug development. She was involved in the discovery of the Company's lead therapeutic antibody KappaMab and in taking the antibody from the laboratory through to pre-clinical and clinical development. Rosanne was also involved in the design of the KMA.CART construct and heads the HaemaLogiX team in the pre-clinical development, translational studies and clinical development program. She is also responsible for the pre-clinical and translational studies of the Company’s LambdaMab antibodies, LMA.CAR-T cell and bispecific antibody development. Rosanne is an inventor on the Company’s patents and was awarded a Ph.D. in antibody engineering from the University of Technology, Sydney.